From the Journals

Hodgkin lymphoma survival has nearly tripled since the 1950s


 

FROM JAMA

Five-year relative survival for Hodgkin lymphoma increased 189% over the approximately 60 years from the early 1950s to 2013, according to investigators looking at data from the Surveillance, Epidemiology, and End Results Program.

During 1950-1954, the 5-year relative survival rate for Hodgkin lymphoma was 30%, compared with 86.6% in 2008-2013, said Ali H. Mokdad, PhD, and his associates at the Institute for Health Metrics and Evaluation at the University of Washington, Seattle.

Five-year survival up 189% for Hodgkin lymphoma
Hodgkin lymphoma was 1 of only 6 of the 29 cancers included in the analysis that had a 5-year survival rate of above 85%. The other five were breast cancer, melanoma, prostate cancer, testicular cancer, and thyroid cancer, the investigators noted (JAMA 2017;317[4]:388-406).

In 2014, mortality for Hodgkin lymphoma was 0.4 per 100,000 population, which put it 27th among the 29 included cancers, with about 36,000 years of life lost, which was 26th of the 29 cancers, Dr. Mokdad and his associates said. This part of their study used deidentified death records from the National Center for Health Statistics and population counts from the Census Bureau, the NCHS, and the Human Mortality Database.

Recommended Reading

Brentuximab vedotin boosted PET-negative rate in Hodgkin
MDedge Hematology and Oncology
Follicular lymphoma with histologic transformation may merit ASCT
MDedge Hematology and Oncology
Adding obinutuzumab to bendamustine boosts progression-free survival in rituximab-refractory indolent non-Hodgkin lymphoma
MDedge Hematology and Oncology
Bendamustine-based chemotherapy induces high CR rate in relapsed HL
MDedge Hematology and Oncology
Long-term analysis shows dwindling RT benefit for DLBCL
MDedge Hematology and Oncology
Triptorelin doesn’t prevent ovarian failure in young women treated for lymphoma
MDedge Hematology and Oncology
Expert panel offers treatment recommendations in Waldenström macroglobulinemia
MDedge Hematology and Oncology
Antibody face-off in follicular lymphoma gives PFS, but not OS, edge to obinutuzumab
MDedge Hematology and Oncology
VIDEO: Obinutuzumab bests rituximab for PFS in follicular lymphoma
MDedge Hematology and Oncology
FDA approves ibrutinib for refractory MZL
MDedge Hematology and Oncology